For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.
|Videos|January 10, 2018
Examining Response Rates in MSI-H and NTRK Fusion GI Cancers
Author(s)Luis A. Diaz, M.D.
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Advertisement
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.
Advertisement
Related to this article
Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.
In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.
Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.
Advertisement
Advertisement
Trending on CURE
1
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
2
My Sister and I Share a BRCA2 Mutation. We Didn’t Make the Same Choices
3
We Eat Bagels Before Cancer Treatment. Here’s Why.
4
I’m Jealous of the World — and Grateful I Got to Be Part of It
5